Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa-Reference-Cited by-同舟云学术

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa

Published:2022-07 Issue:7 Volume:25 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc.

Author:

Romo Matthew L.¹^ORCID,Brazier Ellen¹^ORCID,Mahambou‐Nsondé Dominique²,De Waal Reneé³^ORCID,Sekaggya‐Wiltshire Christine⁴^ORCID,Chimbetete Cleophas⁵^ORCID,Muyindike Winnie R.⁶^ORCID,Murenzi Gad⁷^ORCID,Kunzekwenyika Cordelia⁸^ORCID,Tiendrebeogo Thierry⁹^ORCID,Muhairwe Josephine A.¹⁰^ORCID,Lelo Patricia¹¹,Dzudie Anastase¹²^ORCID,Twizere Christelle¹³^ORCID,Rafael Idiovino¹⁴,Ezechi Oliver C.¹⁵^ORCID,Diero Lameck¹⁶^ORCID,Yotebieng Marcel¹⁷^ORCID,Fenner Lukas¹⁸^ORCID,Wools‐Kaloustian Kara K.¹⁹^ORCID,Shah N. Sarita²⁰,Nash Denis¹^ORCID,

Affiliation:

1. Department of Epidemiology and Biostatistics & Institute for Implementation Science in Population Health CUNY Graduate School of Public Health and Health Policy City University of New York New York New York USA

2. Centre de traitement ambulatoire de Brazzaville enceinte CHU de Brazzaville Brazzaville Congo

3. Centre for Infectious Disease Epidemiology and Research School of Public Health and Family Medicine University of Cape Town Cape Town South Africa

4. Infectious Diseases Institute Makerere University Kampala Uganda

5. Newlands Clinic Harare Zimbabwe

6. Department of Internal Medicine Faculty of Medicine Mbarara University of Science and Technology Mbarara Uganda

7. Research for Development (RD Rwanda) and Rwanda Military Hospital Kigali Rwanda

8. SolidarMed Masvingo Zimbabwe

9. University of Bordeaux Inserm French National Research Institute for Sustainable Development (IRD) Bordeaux Population Health Research Center Bordeaux France

10. SolidarMed Maseru Lesotho

11. Kalembelembe Pediatric Hospital Kinshasa Democratic Republic of the Congo

12. Clinical Research Education Networking and Consultancy Yaoundé Cameroon

13. Centre National de Référence en matière de VIH/SIDA (CNR) Bujumbura Burundi

14. SolidarMed Ancuabe Mozambique

15. Clinical Sciences Department Nigerian Institute of Medical Research Lagos Nigeria

16. School of Medicine College of Health Sciences Moi University Eldoret Kenya

17. Department of Medicine Albert Einstein College of Medicine Bronx New York USA

18. Institute of Social and Preventive Medicine University of Bern Bern Switzerland

19. Department of Medicine Indiana University School of Medicine Indianapolis Indiana USA

20. Division of Infectious Diseases Emory University School of Medicine & Emory University Rollins School of Public Health Atlanta Georgia USA

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25961

Reference36 articles.

1. World Health Organization.Update of recommendations on first‐ and second‐line antiretroviral regimens: policy brief.2019[cited 2022 March 11]. Available from:https://www.who.int/hiv/pub/arv/arv‐update‐2019‐policy/en/.

2. World Health Organization.Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring: recommendations for a public health approach.2019[cited 2022 March 11]. Available from:https://www.who.int/publications/i/item/9789240031593.

3. Clinton Health Access Initiative.HIV Market Report 2020; Issue 11.2020[cited 2022 March 11]. Available from:https://www.clintonhealthaccess.org/the‐state‐of‐the‐hiv‐market‐in‐low‐and‐middle‐income‐countries‐3/.

4. Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025

5. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking barriers: The potential of nanosystems in antituberculosis therapy;Bioactive Materials;2024-09

2. Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With Human Immunodeficiency Virus From 6 Countries;Clinical Infectious Diseases;2024-05-13

3. Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts;Open Forum Infectious Diseases;2024-03-19

4. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study;AIDS Research and Human Retroviruses;2024-01-05

5. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study;The Lancet HIV;2023-05